FindTrial
Sign In

Mexidol

DRUG8 trials

Sponsors

Pharmasoft

Conditions

Anxiety Disorders and SymptomsAttention Deficit Hyperactivity Disorder (ADHD)Chronic Cerebral IschemiaIschemic StrokeIschemic Stroke, AcutePrimary Open-Angle Glaucoma (POAG)Vascular Cognitive Impairment no Dementia

Phase 2

Efficacy and Safety of Different Dosages of Mexidol® in Patients With Primary Open-angle Glaucoma (POAG)
CompletedNCT06903156
PharmasoftPrimary Open-Angle Glaucoma (POAG)
Start: 2021-11-15End: 2023-09-07Updated: 2025-12-12

Phase 3

Study of Efficacy and Safety of MEXIDOL® in Ischemic Stroke Therapy
CompletedNCT02793687
PharmasoftIschemic Stroke
Start: 2015-03-06End: 2016-05-27Updated: 2025-02-24
Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral Ischemia
CompletedNCT06834490
PharmasoftChronic Cerebral Ischemia
Start: 2019-11-05End: 2020-12-08Updated: 2025-10-06
Safety and Efficacy of Mexidol® for ADHD in Children Aged 6-12
CompletedNCT06854601
PharmasoftAnxiety Disorders and Symptoms, Attention Deficit Hyperactivity Disorder (ADHD)
Start: 2019-07-13End: 2020-07-13Updated: 2025-08-17

Phase 4

MEXIDOL® in the Rehabilitation Treatment of Patients With Acute Cerebral Failure
CompletedNCT06221826
PharmasoftIschemic Stroke, Acute
Start: 2023-04-17End: 2023-09-12Updated: 2025-04-27
MEXIDOL® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG)
CompletedNCT06437639
PharmasoftPrimary Open-Angle Glaucoma (POAG)
Start: 2023-09-15End: 2024-02-02Updated: 2025-12-12
Mexidol® Safety and Efficacy in Treatment of Hyperacute and Acute Ischemic Stroke
RecruitingNCT07575984
PharmasoftIschemic Stroke
Start: 2025-11-04End: 2027-04-01Target: 120Updated: 2026-05-13
Mexidol® Efficacy and Safety in Treatment of VCIND in Older Adults
CompletedNCT07700615
PharmasoftVascular Cognitive Impairment no Dementia
Start: 2025-09-14End: 2025-11-05Updated: 2026-07-14